Patents Assigned to IRM LLC
  • Methods and compositions for modulating cell proliferation
    Patent number: 7252944
    Abstract: This invention provides methods for identifying novel SHMT modulators. The methods comprise first screening test agents for modulators of p38 activity and then further screening the identified modulating agents for modulators of SHMT enzyme activity. The invention further provides methods and pharmaceutical compositions for modulating cellular proliferation and for treating tumors using the novel SHMT modulators.
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: August 7, 2007
    Assignee: IRM LLC
    Inventors: Kavita Shah, Sungjoon Kim
  • Immunosuppressant compounds and compositions
    Publication number: 20070167410
    Abstract: The present invention relates to immunosuppressants, processes for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
    Type: Application
    Filed: February 24, 2005
    Publication date: July 19, 2007
    Applicant: IRM LLC
    Inventors: Shifeng Pan, Wenqi Gao, Nathanael Gray, Yuan Mi
  • Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors
    Publication number: 20070149538
    Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.
    Type: Application
    Filed: September 26, 2006
    Publication date: June 28, 2007
    Applicants: IRM LLC, Novartis, AG
    Inventors: Valentina Molteni, Xiaolin Li, Donatella Chianelli, Jon Loren, Shuli You, Juliet Nabakka, Xiadong Liu, Shifeng Pan, Yi Liu, Donald Karanewsky, Pascal Furet, Vito Guagnano
  • Methods and compositions for inducing apoptosis in cancer cells
    Patent number: 7229617
    Abstract: Anti-DR4 or Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: June 12, 2007
    Assignee: IRM LLC
    Inventors: Marc Nasoff, Quinn L. Deveraux, Deborah A. Knee, Pedro Aza-Blanc, Garret M. Hampton, Klaus Wagner
  • Universal G-protein coupled receptor reporter constructs
    Patent number: 7229768
    Abstract: The present invention provides universal G protein-coupled receptor (GPCR) reporter constructs. The constructs comprise a serum response element, a cAMP response element, and a multiple response element. These reporter constructs are able to detect activities of all GPCRs examined. Further provided by the present invention are host cells harboring a universal GPCR reporter construct of the invention, as well as assays for detecting modulators of GPCRs using the host cells.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: June 12, 2007
    Assignee: IRM LLC
    Inventors: Yinghe Hu, Cecilia Jiang
  • Methods and compositions for inducing apoptosis in cancer cells
    Publication number: 20070128204
    Abstract: Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.
    Type: Application
    Filed: December 1, 2006
    Publication date: June 7, 2007
    Applicant: IRM LLC
    Inventors: Marc Nasoff, Quinn Deveraux, Deborah Knee, Pedro Aza-Blanc, Garret Hampton, Klaus Wagner
  • INHIBITORS OF CATHEPSIN S
    Publication number: 20070123523
    Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
    Type: Application
    Filed: January 5, 2007
    Publication date: May 31, 2007
    Applicant: IRM LLC
    Inventors: Hong Liu, David Tully, Phillip Alper, Robert Epple, Arnab Chatterjee, Michael Roberts
  • Automated cellular assaying systems and related components and methods
    Publication number: 20070105214
    Abstract: High throughput and automated cellular disruption systems that substantially uniformly disrupt cells as part of cellular motility assays as wells as other assay types are provided. In addition, various system components, including holding blocks, holding block loading devices, and system software, are also provided. Moreover, related methods that utilize these systems and system components are additionally provided.
    Type: Application
    Filed: November 9, 2005
    Publication date: May 10, 2007
    Applicants: IRM, LLC, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Kenneth Micklash, Jiyong Hong, James Mainquist, Sheng Ding, Robert Downs, Peter Schultz
  • Oxindoles with anti-HIV activity
    Patent number: 7205328
    Abstract: The present invention relates to inhibition of viruses, e.g., HIV using oxindoles and compounds related to oxindoles. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.
    Type: Grant
    Filed: October 21, 2003
    Date of Patent: April 17, 2007
    Assignee: IRM LLC
    Inventors: Yun He, Tao Jiang, Kelli L. Kuhen, David Archer Ellis, Baogen Wu, Tom Yao-Hsiang Wu, Badry Bursulaya
  • Methods and compositions as protein kinase inhibitors
    Patent number: 7189729
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, EGF-R, c-erbB2 kinase (HER-2), CHK2, FGFR3, p70S6K, PKC, PDGF-R, p38, TGF?, KDR, c-Kit, b-RAF, c-RAF, FLT1 and/or FLT4 kinases.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: March 13, 2007
    Assignee: IRM LLC
    Inventors: Greg Chopiuk, Pascal Furet, Nathanael Schiander Gray, Patricia Imbach, Yi Liu, Joseph Schoepfer, Ruo Steensma
  • Methods and compositions for inhibiting herpesviral replication
    Patent number: 7179619
    Abstract: This invention provides methods of screening for compounds that inhibit herpesviral transcription and replication. The methods comprise screening test compounds for ability to enhance the activity of homeodomain transcription factor PDX1 in repressing transcription of herpesviral genes (e.g., the IE gene of cytomegalovirus). Transcriptional repression by PDX1 can be monitored using an expression vector comprising a reporter gene operably linked to a PDX1-binding, upstream transcription regulatory sequence of the herpesvirus. The invention further provides methods and pharmaceutical compositions for stimulating PDX1-mediated transcriptional repression in a subject and for treating diseases and conditions associated with herpesviral infection.
    Type: Grant
    Filed: July 7, 2004
    Date of Patent: February 20, 2007
    Assignee: IRM LLC
    Inventors: Sheng-Hao Chao, Jeremy S. Caldwell
  • Kinase inhibitor scaffolds and methods for their preparation
    Patent number: 7176312
    Abstract: General methods for the solution phase as well as solid phase synthesis of various substituted heteroaryls has been demonstrated. These substituted heteroaryls can be further elaborated by aromatic substitution with amines at elevated temperature or by anilines, boronic acids and phenols via palladium catalyzed cross-coupling reactions.
    Type: Grant
    Filed: October 12, 2002
    Date of Patent: February 13, 2007
    Assignees: The Scripps Research Institute, IRM LLC
    Inventors: Sheng Ding, Qiang Ding, Nathanael S. Gray
  • Inhibitors of cathepsin S
    Patent number: 7173051
    Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: February 6, 2007
    Assignee: IRM, LLC
    Inventors: Hong Liu, David Tully, Phillip Alper, Robert Epple, Arnab Chatterjee, Michael Roberts
  • Bis-aromatic alkanols
    Patent number: 7169817
    Abstract: The present invention relates to biphenylyl derivatives, processes for their production, their uses and pharmaceutical compositions containing them. Compounds according to the present invention are based upon the chemical formula: wherein the substituents have the values mentioned herein.
    Type: Grant
    Filed: May 27, 2003
    Date of Patent: January 30, 2007
    Assignee: IRM LLC
    Inventors: Shifeng Pan, Nathanael S. Gray, Wenqui Gao, Klaus Hinterding, Sophie Lefebvre, Yuan Mi, Peter Nussbaumer, Wei Wang, Federic Zecri, Fan Yi, Lawrence Blas Perez, Kenneth Richad la Montagne, Peter Ettmayer
  • Methods and compositions for inhibiting HIV infection
    Publication number: 20060286036
    Abstract: This invention provides novel methods for identifying agents that inhibit HIV infection. The anti-HIV agents are identified by screening test compounds for ability to modulate a biological activity of isopeptidase T (IsoT), e.g., its isopeptidase activity or its binding to another molecule such as viral protein R (Vpr). Such IsoT modulators can be further examined for their activity in inhibiting an activity indicative of HIV infection or HIV replication. These novel anti-HIV agents are useful in the prevention or treatment of HIV infection and conditions associated with or caused by HIV infection.
    Type: Application
    Filed: April 21, 2006
    Publication date: December 21, 2006
    Applicant: IRM LLC
    Inventors: Kelli Kuhen, Jeremy Caldwell
  • Cyclic compounds and compositions as protein kinase inhibitors
    Patent number: 7151096
    Abstract: The invention provides a novel class of cyclic compounds, pharmaceutical compositions comprising such cyclic compounds and methods of using such compounds to treat or prevent diseases and disorders associated with cyclin-dependent kinases (CDKs) activity, particularly diseases associated with the activity of CDK2 and CDK5.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: December 19, 2006
    Assignee: IRM LLC
    Inventors: Pingda Ren, Francisco Adrian, Nathanael S. Gray, Xia Wang
  • High throughput incubation devices and systems
    Publication number: 20060270027
    Abstract: The invention provides efficiently automated incubation devices that reduce the number of powered moving parts in the devices and the amount of air transfer between environments that are internal and external to the devices. Related systems are also provided.
    Type: Application
    Filed: May 27, 2005
    Publication date: November 30, 2006
    Applicant: IRM LLC
    Inventors: Christopher Shaw, Robert Downs
  • Transient receptor potential channel TRPV3 and its use
    Publication number: 20060251648
    Abstract: This invention provides novel genes and polypeptides of the transient receptor potential channel family, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.
    Type: Application
    Filed: March 20, 2006
    Publication date: November 9, 2006
    Applicants: IRM LLC, Novartis AG
    Inventors: Stuart Bevan, Pamposh Ganju, Peter McIntyre, Ardem Patapoutian, Andrea Peier, Chuanzheng Song
  • Differential tumor cytotoxicity compounds and compositions
    Patent number: 7125997
    Abstract: The invention is directed to novel biaryl derivatives, to the uses of these compounds in various medicinal applications, including the treatment, prevention and control of proliferative diseases such as tumors, and to pharmaceutical compositions comprising these compounds. Compounds of the invention can be used to treat or prevent diseases or disorders that involve the activity of MIF-1 and/or adenosine kinase.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: October 24, 2006
    Assignee: IRM LLC
    Inventors: Jason Chyba, Quinn Devereax, Garret Hampton, Fred King
  • Vanilloid receptor-related nucleic acids and polypeptides
    Patent number: 7115414
    Abstract: This invention provides novel genes and polypeptides of the VR family, identification of trkA+ pain specific genes expressed in the DRG, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: October 3, 2006
    Assignees: IRM LLC, A Delaware Corp., Novartis AG
    Inventors: Stuart Bevan, Pamposh Ganju, Peter McIntyre, Ardem Patapoutian, Andrea Peier, Chuanzheng Song